Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	51.39B +6.0%
Revenue (ttm)	28.20B +10.5%
Net Income	4.22B +18.7%
EPS	79.68 +18.7%
Shares Out	52.98M
PE Ratio	12.17
Forward PE	11.75
Dividend	50.00 (5.16%)
Ex-Dividend Date	Apr 22, 2026

Volume	19,146
Open	968.17
Previous Close	n/a
Day's Range	951.30 - 974.00
52-Week Range	755.56 - 1,241.00
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiary, engages in the development, production, marketing, and distribution of pharmaceutical and allied consumer products in Pakistan, Afghanistan, the United Arab Emirates, Sri Lanka, France, Sudan, Cambodia, Kenya, Iraq, Dubai, Tanzania, and internationally. The company offers medicines in various drug forms and brands for allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynecology, pediatrics, respiratory, and urology therapeutic areas. It ...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,563
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2025, Highnoon Laboratories's revenue was 27.71 billion, an increase of 12.44% compared to the previous year's 24.64 billion. Earnings were 4.13 billion, an increase of 21.83%.